PREVENTION AND MONITORING OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER

PREVENTION AND MONITORING OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER

Myocardial dysfunction, heart failure and prolongation of the QTc interval are dangerous cardiovascular complications associated with systemic treatment for luminal HER2-negative metastatic breast cancer. Special monitoring is required to control such complications, especially when introducing new d...

Full description

Saved in:

Bibliographic Details
Main Authors:	N. A. Kozyavin, T. Yu. Semiglazova
Format:	Article
Language:	Russian
Published:	ABV-press 2018-08-01
Series:	Опухоли женской репродуктивной системы
Subjects:	myocardial dysfunction heart failure qtc interval prolongation cyclin-dependent kinases luminal her2-negative metastatic breast cancer
Online Access:	https://ojrs.abvpress.ru/ojrs/article/view/595
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Treatment of luminal HER2-negative breast cancer: opinion of experts
by: E. V. Artemeva, et al.
Published: (2024-06-01)

HORMONE-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER: DECISION MAKING IN REAL CLINICAL PRACTICE
by: L. Yu. Vladimirova, et al.
Published: (2020-06-01)

QT STAR: concomitant QTc-prolonging medication use among patients with HR+/HER2− metastatic breast cancer receiving a CDK4/6 inhibitor in first line
by: Susan Dent, et al.
Published: (2025-07-01)

A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer
by: Xiangjun Li, et al.
Published: (2025-07-01)

Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors
by: E. V. Artamonova, et al.
Published: (2019-09-01)

Research progress on cell cycle regulation-related molecules in the development of oral squamous cell carcinoma
by: HOU Zeyu, et al.
Published: (2023-04-01)

Real-World, National Study of Palbociclib in HR+/HER2− Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021
by: Cristina Marinela Oprean, et al.
Published: (2025-05-01)

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review
by: N. A. Avxentyev, et al.
Published: (2024-05-01)

Loperamide poisoning resulting in death: a case report and literature review
by: Bowen Wang, et al.
Published: (2025-08-01)

QT-Interval Prolongation in the Treatment of Drug-Resistant Tuberculosis
by: A. V. Kukurika
Published: (2024-03-01)

The effect of the current chemotherapy of MDR/XDR tuberculosis on QT interval changes in ECG
by: E. M. Zhukova, et al.
Published: (2019-12-01)

Grade III rash induced by abemaciclib in a patient with HR+/HER-2 negative breast cancer
by: Yu Yao, et al.
Published: (2025-05-01)

Clinical and morphological aspects of neoadjuvant chemotherapy efficacy in patients with aggressive luminal HER2-negative breast cancer
by: D. A. Morozov, et al.
Published: (2022-01-01)

QTc prolongation and dysrhythmia risk in emergency department patients administered ondansetron
by: Evan Lawyer, et al.
Published: (2025-06-01)

Risk prediction of QTc prolongation occurrence in cancer patients treated with commonly used oral tyrosine kinase inhibitors: machine learning modeling or conventional statistical analysis better?
by: Hsiang-Wen Lin, et al.
Published: (2025-08-01)

Prognostic significance of the Tpe/Qtc ratio in predicting major adverse cardiac events in acute STEMI patients
by: Evren Dal, et al.
Published: (2025-07-01)

THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS
by: S. L. Pavlinsky, et al.
Published: (2017-09-01)

Influence of various angles and distances on luminance measurement results
by: Jan Bartoníček, et al.
Published: (2025-06-01)

Large‐Scale Analysis of Age and Sex Effects on Corrected QT and JT Intervals: Insights From Hospital‐Based Controls and Moxifloxacin‐Treated Cases
by: Eunwoo Kim, et al.
Published: (2025-06-01)

Efficacy of cyclin-dependent kinases 4 and 6 inhibitors in the treatment of HR +/HER2 − advanced breast cancer: a meta-analysis
by: Isah Adamu Danbala, et al.
Published: (2025-06-01)

Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer
by: Christina B. Walter, et al.
Published: (2025-04-01)

Alcohol-induced changes in the serum of vascular endothelial growth factor and electrical inhomogeneity of the myocardium in young patients
by: P. V. Belogubov, et al.
Published: (2022-03-01)

Study of cytostatic and cytotoxic characteristics of modified peptide CDK4/6 inhibitors – functional analogs of p16INK4a (90-97)
by: V. K. Bozhenko, et al.
Published: (2021-01-01)

HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014-07-01)

PALBOCICLIB IN COMBINATION WITH HORMONE THERAPY FOR LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER: NEW HIGHLY EFFECTIVE STRATEGY OF DRUG TREATMENT
by: E. V. Artamonova
Published: (2017-09-01)

Association of QTc prolongation with liver function test and complications in patients with cirrhosis: An observational study
by: Rhythm Yogandh Relekar, et al.
Published: (2025-06-01)

Discordance of HER2 between primary tumors and lymph node metastatic lesions in invasive breast cancer
by: Noviana Nugrohowati, et al.
Published: (2025-02-01)

Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Radiotherapy in Curative Breast Cancer Patients Induced Pneumonitis: A Case Report
by: Pei-Yu Hou
Published: (2025-04-01)

Decidual natural killer cells and trophoblast cells: cellular, humoral and molecular mechanisms of interaction
by: P. V. Grebenkina, et al.
Published: (2022-12-01)

Cyclin dependent kinase 9 inhibitor induces transcription-replication conflicts and DNA damage accumulation in breast cancer
by: Minyoung Lee, et al.
Published: (2025-07-01)

Exploring the Therapeutic Potential of Antiaris africana: Targeting Cyclin-Dependent Kinases 8 and 13 for Cancer Treatment through Molecular Docking Studies
by: Mutiu A. Alabi, et al.
Published: (2025-06-01)

Management of Diffuse Carcinomatosis of the Bone Marrow from Occult Breast Cancer with Abemaciclib and Letrozole: Case Report and Literature Review
by: Ketan Makwana, et al.

Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis
by: George W. Jr. Sledge, et al.
Published: (2025-08-01)

The impact of ROR1, BMI-1 expression and <i>PIK3CA</i> mutation on the prognosis of luminal breast cancer
by: S. V. Vtorushin, et al.
Published: (2025-05-01)

ADJUVANT CHEMOTHERAPY OF PRIMARY OPERABLE LUMINAL B BREAST CANCER WITHOUT OVEREXPRESSION OF HER2/NEU IN POSTMENOPAUSAL WOMEN: YES OR NO?
by: Yu. S. Shatova, et al.
Published: (2017-12-01)

Real-world treatment patterns and outcomes among patients with HER2-positive unresectable or metastatic breast cancer in China
by: Jiajia Huang, et al.
Published: (2025-05-01)

Evolution of systemic treatment for hormone-sensitive breast cancer: from sequential use of single agents to the upfront administration of drug combinations
by: E. N. Imyanitov
Published: (2016-09-01)

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy
by: Charles E. Geyer, Jr., et al.
Published: (2025-06-01)

Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review
by: Herleeyana Meriyani, et al.
Published: (2025-02-01)

Assessment of <i>ERBB2</i> and HER2 expression in metastatic breast cancer using the nCounter® system and a 100-gene scale
by: R. M. Paltuev, et al.
Published: (2023-10-01)